Back to Search
Start Over
Projecting Long-term Health and Economic Burden of COPD in the United States
- Source :
- Chest. 159(4)
- Publication Year :
- 2020
-
Abstract
- Background In the United States, COPD is a leading cause of mortality, with a substantial societal health and economic burden. With anticipated population growth, it is important for various stakeholders to have an estimate for the projected burden of disease. Research Question The goal of this study was to model the 20-year health and economic burden of COPD, from 2019 to 2038, in the United States. Study Design and Methods Using country-specific data from published literature and publicly available datasets, a dynamic open cohort Markov model was developed in a probabilistic Monte Carlo simulation. Population growth was modeled across different subgroups of age, sex, and smoking. The COPD prevalence rates were calibrated for different subgroups, and distributions of severity grades were modeled based on smoking status. Direct costs, indirect absenteeism costs, losses of quality-adjusted life years (QALYs), and number of exacerbations and deaths associated with COPD were projected. Results The 20-year discounted direct medical costs attributable to COPD were estimated to be $800.90 billion (95% credible interval [CrI], 565.29 billion-1,081.29 billion), with an expected $337.13 billion in male subjects and $463.77 billion in female subjects. The 20-year discounted indirect absenteeism costs were projected to be $101.30 billion (70.82 billion-137.41 billion). The 20-year losses of QALYs, number of exacerbations, and number of deaths associated with COPD were 45.38 million (8.63 million-112.07 million), 315.08 million (228.59 million-425.33 million), and 9.42 million (8.93 million-9.93 million), respectively. The proportion of disease burden attributable to continued smoking was 34% in direct medical costs, 35% in indirect absenteeism costs, and 37% in losses of QALYs over 20 years. Interpretation This study projects the substantial burden of COPD that the American society is expected to incur with current patterns for treatments and smoking rates. Mitigating such burden requires targeted budget appropriations and cost-effective interventions.
- Subjects :
- Pulmonary and Respiratory Medicine
Adult
Male
Psychological intervention
Critical Care and Intensive Care Medicine
Severity of Illness Index
03 medical and health sciences
Indirect costs
Pulmonary Disease, Chronic Obstructive
0302 clinical medicine
Cost of Illness
Environmental health
medicine
Prevalence
Population growth
Humans
030212 general & internal medicine
health care economics and organizations
Disease burden
Aged
COPD
business.industry
Smoking
Health Care Costs
Middle Aged
medicine.disease
Symptom Flare Up
Markov Chains
United States
Quality-adjusted life year
030228 respiratory system
Cohort
Absenteeism
Female
Quality-Adjusted Life Years
Cardiology and Cardiovascular Medicine
business
Monte Carlo Method
Forecasting
Subjects
Details
- ISSN :
- 19313543
- Volume :
- 159
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Chest
- Accession number :
- edsair.doi.dedup.....abf8bc63f518f5aaf41d602d8cdcd981